Biofrontera (BFRI) EBT Growth (3y) (2023 - 2026)
Biofrontera (BFRI) EBT Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 21.00% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.19% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.60% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -29.91% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 10.08% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 39.40% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biofrontera | 18.87 Mn | 14.16 Mn | 9.59 Mn | 61.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.04% |
| Dec 31, 2025 | 59.08% |
| Sep 30, 2025 | -37.33% |
| Jun 30, 2025 | -84.09% |
| Mar 31, 2025 | -40.13% |
| Dec 31, 2024 | 54.13% |
| Sep 30, 2024 | 29.26% |
| Jun 30, 2024 | 59.69% |
| Mar 31, 2024 | -43.48% |
| Dec 31, 2023 | 174.68% |
| Sep 30, 2023 | -29.44% |